BCL9 and breast cancer: The aberrant activation of WNT/β-CATENIN signaling pathway leads to early events in carcinogenesis.352 Increasing evidences indicate that BCL9 and BCL9L transcriptional co-activators are over expressed in a significant population of breast cancer patients,353 and modulate the expression of β-CATENIN to promote tumor growth, cell migration, and metastasis in TNBC models.354 Targeting BCL9/BCL9L has been reported to have efficient anti-tumor effect through the inhibition of WNT and TGF-β signaling pathways, suggesting a viable therapeutic approach for TNBC treatment.355